Guangzhou Yipinhong Pharmaceutical Co., Ltd.

(1) Primary objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetics of AR882 capsules (specification: 25 mg); (2) Secondary objective: To evaluate the safety and tolerability of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. in healthy Chinese subjects; (3) Exploratory objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacodynamics of AR882 capsules (specification: 25 mg).

Primary objective: To compare the differences in absorption extent and absorption rate of the test preparation, nifedipine controlled-release tablets (specification: 30 mg) provided by Guangzhou Yipinhong Pharmaceutical Co., Ltd. and the reference preparation, nifedipine controlled-release tablets (trade name: Baixintong®; specification: 30 mg) certified by Bayer Pharma AG, in healthy Chinese population under fasting and postprandial administration conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese participants under fasting and postprandial conditions.

Main purpose: Pemabet tablets (specification: 0.1 mg) produced by Guangzhou Yipinhong Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant provisions of the bioequivalence test, the relative bioavailability in healthy humans was compared with that of Pemabet tablets (reference preparation, trade name: Parmodia®, specification: 0.1 mg) certified by Kowa Co., Ltd. to investigate the human bioequivalence of the two preparations. Secondary Purpose: To observe the safety of the test formulation of Pemabet tablets (strength: 0.1 mg) and the reference formulation (trade name: Parmodia ®, strength: 0.1 mg) in healthy study participants.